Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | TDO2 | P48775 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10415149 | 0.76 | HTR2A (0.36) | HTR2ATAAR1ALDH1A1TSHRDPP4 | |
| SCHEMBL1225030 | 0.76 | CYP2D6 (0.39) | HTR2ATAAR1TSHRDPP4F2 | |
| SCHEMBL9341987 | 0.73 | HTR2A (0.36) | HTR2ANFE2L2ALDH1A1TSHRMAOB | |
| SCHEMBL3647646 | 0.71 | HTR2A (0.35) | HTR2ANFE2L2ALDH1A1TSHRDPP4 | |
| SCHEMBL9217443 | 0.71 | ALDH1A1 (0.39) | CYP1A2NFE2L2ALDH1A1TSHRMAOB | |
| SCHEMBL3245737 | 0.70 | CYP1A2 (0.36) | HTR2ATAAR1CYP1A2NFE2L2ALDH1A1 | |
| SCHEMBL7366231 | 0.69 | ALDH1A1 (0.39) | HTR2ATAAR1CYP1A2ALDH1A1TSHR | |
| SCHEMBL9011584 | 0.67 | KMT2A (0.36) | ALDH1A1LMNA | |
| SCHEMBL9011583 | 0.67 | KMT2A (0.36) | ALDH1A1LMNA | |
| SCHEMBL9804450 | 0.67 | ALDH1A1 (0.43) | HTR2ATAAR1CYP1A2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | HTR2A 1158/4885TAAR1 436/4885IDO1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.